Sudhakar Bangera, MBBS, MD, MMedSc, Fellow-Vaccinology Managing Partner AILEEN Clinical Research Services AILEEN, India
It’s not just the bacteria or viruses that most commonly cause life-threatening disease in human, some of them could be fungal pathogens. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infe [....] » Read More
Title : Vaccines and monoclonal antibodies in the prolonged treatment of non-small cell lung cancer: 20 years of follow-up
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Lung cancer is the first cause of death from cancer in the world and in some countries as the first cause of death for both sexes. Early diagnosis and timely therapy is successful for increasing the survival of these patients, however, the masking with frequent symptoms of other [....] » Read More
Title : Observational study post emergency use authorization of itolizumab in the treatment of COVID-19
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
COVID-19 continues to be a global health problem, it is a multifactorial disease characterized by a process of hyperinflammation. Itolizumab, a humanized anti-CD6 mAb, has the Emergency Use Authorization (UEA) for patients with this disease with signs of hyperinflammation. Method [....] » Read More
Title : Vaccine for AML: 2023 and beyond
Stefan Gluck, Jessica McDonough PhD Co-Founder Attivare, United States
The idea of using the immune system to fight cancer is over 100 years old. (Paul Ehrlich’s “Magic Bullet”). New cellular and molecular approaches over the last 2 decades or so, led to a better understanding of the immune system. Our focus became the T cell, its [....] » Read More
Title : Purification process development of COVID antigens to identify sera needed for plasma therapy
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States
One of the crucial steps in deploying plasma therapy for COVID-19 has been the development of critical assays to detect SARS-CoV-2 antibodies and evaluate their potential suitability. Unfortunately, assays that assess neutralizing antibodies involve use of live SARS-CoV-2 virus i [....] » Read More
Title : Lessons that can be learned from the rollout of the COVID-19 vaccine and the acceptance of vaccination from healthcare professionals, frontline workers and patients that need to be considered in developing a vaccine
Regina Au, BioMarketing insight, United States
When the COVID-19 Vaccine was developed, time was crucial and the pharmaceutical and biotechnology companies primary goal was to get a vaccine out as soon as possible so people to get vaccinated in saving lives. What wasn't considered which most large companies co [....] » Read More
Title : Lessons learned for the future of social listening to address vaccine misinformation
Joseph Smyser, The Public Good Projects, United States
Introduction: As the pandemic evolves and nations refocus on routine immunizations and vaccine-preventable outbreaks, it is critical to continue increasing vaccine demand. Misinformation threatens the success of vaccination programs across the world. Since 2017, The Public Good P [....] » Read More
Title : Why Low-Energy-Electron Irradiation might be a potential game changer for vaccine development, manufacturing, and pandemics prevention
Daniel Becker, KyooBe Tech GmbH, Germany
In the ongoing global Covid-19 aftermath, epidemics and pandemics triggered by microbial and viral pathogens remain a significant challenge for global vaccine production and worldwide supply. The Irradiation of target pathogens with low-energy electrons (LEEI) can reliably and [....] » Read More
Title : National immunization management system- NIMS
Kashif Zulfiqar, Project Manager - NADRA, Pakistan
National Immunization Management System (NIMS) in Pakistan envisages to consolidate all immunization activities that are being carried out in the country, on a single intelligent platform including vaccination scheduling, vaccine administration, role based reporting, complaint [....] » Read More
Title : Medicinal synthetic aluminum-magnesium silicate {Al4 (SiO4)3 + 3Mg2SiO4?2Al2 Mg3 (SiO4)3} effective for: Viral diseases; Tumors; Antimicrobial resistant infections
Maduike Chiehiura Onwubiko Ezeibe, Michael Okpara University of Agriculture, Nigeria
Viral diseases, cancers (tumors) and antimicrobial resistant infections are among the world`s biggest health challenges. Literature reveals, that HIV and COVID-19 virus (RNA viruses) are positively charged while DNA viruses and abnormal (tumor/infected) cells are negatively charg [....] » Read More
Title : Moving the needle for covid-19 vaccinations in Nigeria through leadership, accountability, and transparency
Fejiro Chinye Nwoko, Nigeria Solidarity Support Fund, Nigeria
Background: The first set of vaccines arrived in Nigeria in March 2021. The National Primary Health Care Development Agency (NPHCDA) set out to vaccinate at least 70% percent of Nigeria’s eligible population i.e., 111,776,503 people, by December 2022. As of June 2021, only [....] » Read More
Title : Measles immunization research western lake state, South Sudan
Nebiyu Lera Alaro, Medecins Sans Frontieres, Ethiopia
Most global estimates indicate that more than 1 million children a year die from acute measles. The actual number of deaths may, however, be considerably higher than this. In addition, the impact of delayed mortality as a result of measles infection is only now being realized. Ma [....] » Read More
Title : Assessment of health workers knowledge and practiceson vaccines storage and cold chain management in the Techiman Municipality.
Carless Gyamfuaa Ameyaw, Holy Family Hospital, Ghana
Background: The contribution of immunization to humanity is invaluable, especially to children. This makes assessment of the vaccine cold chain system of any immunization programme crucial to determine its strengths and weaknesses at all levels. The World Health Organization and [....] » Read More
Title : Developing a network: supporting SARS-CoV-2 assays vaccine clinical trials through the CEPI Centralized Laboratory Network.
Bethan Charlotte Hussey, UK Health Security Agency, United Kingdom
The UK Health Security Agency (UKHSA) has longstanding expertise in the technological support of vaccine development through a vast array of immunological assays. In early 2020, using this valuable knowledge, scientists within UKHSA were able to rapidly develop a live virus micro [....] » Read More
Title : Reactive arthritis following mpox monkey pox vaccination
Indira Acharya, Medstar, United States
however ANA, rheumatoid factor Reactive arthritis after various vaccinations has been previously described but such kind of reaction after mpox vaccination has not been previously reported. Here we present a case of recently diagnosed reactive arthritis following intradermal mpox [....] » Read More
Title : Challenges experienced, strategies adopted, and lessons learned while conducting a phase III clinical trial for COVID-19 vaccine in nepal
Navneet Bichha, IIHMR University, India
Background: The global outbreak of COVID-19 has had a substantial effect on the conduct of scientific research worldwide with a need for fast-track evidence generation in vaccine development through newer innovations and technologies to control the spread of infection and reduce [....] » Read More
Title : management of arterial hypertension and diabetes in elderly people as well as COVID-19 prevention
Nzolameso makaya Jennifer, Hopital general de reference de kimbanseke pierre fokom, Congo
70% of people over 65 are hypertensive; high blood pressure increases the risk of exposure to cardiovascular disease (myocardial infarction and heart failure) and stroke. This is a public health problem, given the aging of the population. There are few studies carried out in e [....] » Read More
Title : The impact of COVID-19 on HPV vaccination: "Examining the role of stakeholders in sustaining demand and equity post-pandemic.
Vincent Omondi, Clinton Health Access Initiative, Kenya
The COVID-19 pandemic has had a significant impact on global healthcare services, including routine immunization programs. In particular, the pandemic has disrupted human papillomavirus (HPV) vaccination efforts, which are critical in preventing HPV-related cancers. This review e [....] » Read More
Title : Defense mechanisms against MERS-CoV infection and immunological memory in human mucosal tissues for designing intranasal vaccines candidates.
Khalid Jebril Shrwani, Public Health Authority, Saudi Arabia
Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a deadly pathogen with a mortality rate of up to 34.4% that can cause severe respiratory tract disease and multiorgan failure. Therefore, there is a pressing need for both successful antiviral vaccines and eff [....] » Read More